Long-Term Results of 0.19mg Fluocinolone Acetonide Insert for Treatment of Non-Infectious Uveitis in Clinical Practice.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY Ocular Immunology and Inflammation Pub Date : 2024-09-01 Epub Date: 2023-09-01 DOI:10.1080/09273948.2023.2250431

Lara Buhl, Valerie Schmelter, Benedikt Schworm, Stephan Thurau, Christoph Kern

{"title":"Long-Term Results of 0.19mg Fluocinolone Acetonide Insert for Treatment of Non-Infectious Uveitis in Clinical Practice.","authors":"Lara Buhl, Valerie Schmelter, Benedikt Schworm, Stephan Thurau, Christoph Kern","doi":"10.1080/09273948.2023.2250431","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the long-term outcomes of patients with non-infectious uveitis treated with 0.19 mg fluocinolone acetonide insert (FAi) for up to 36 months in clinical practice.Methods: A retrospective study conducted at a single uveitis center.Results: Fifty eyes of 39 patients were included. Mean best corrected visual acuity (BCVA) and central retinal thickness (CRT) remained stable until month 36 after FAi implantation (61.04 vs. 70.25 letters and 370.8 vs. 332.5 µm, respectively). The recurrence rate was 34% (17 eyes) after 36 months, of which 82% (14 eyes) received high-dose corticosteroids before FAi. Mean intraocular pressure (IOP) remained unchanged (13.38 vs. 15.74 mmHg), while most phakic eyes (13 of 14 eyes) required cataract surgery.Conclusions: We show that FAi effectively prevents recurrences of non-infectious uveitis for up to three years in clinical practice, comparable with randomized clinical trials. Patients who received high-dose corticosteroids before FAi have an increased risk for early recurrence and should be considered for scheduled re-treatment.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2023.2250431","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the long-term outcomes of patients with non-infectious uveitis treated with 0.19 mg fluocinolone acetonide insert (FAi) for up to 36 months in clinical practice.

Methods: A retrospective study conducted at a single uveitis center.

Results: Fifty eyes of 39 patients were included. Mean best corrected visual acuity (BCVA) and central retinal thickness (CRT) remained stable until month 36 after FAi implantation (61.04 vs. 70.25 letters and 370.8 vs. 332.5 µm, respectively). The recurrence rate was 34% (17 eyes) after 36 months, of which 82% (14 eyes) received high-dose corticosteroids before FAi. Mean intraocular pressure (IOP) remained unchanged (13.38 vs. 15.74 mmHg), while most phakic eyes (13 of 14 eyes) required cataract surgery.

Conclusions: We show that FAi effectively prevents recurrences of non-infectious uveitis for up to three years in clinical practice, comparable with randomized clinical trials. Patients who received high-dose corticosteroids before FAi have an increased risk for early recurrence and should be considered for scheduled re-treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗非感染性葡萄膜炎的 0.19 毫克阿塞通氟西酮栓剂临床实践的长期结果。

目的：评估临床实践中使用0.19毫克氟西诺龙醋酸内酯（FAi）治疗非感染性葡萄膜炎患者长达36个月的长期疗效：方法：在一家葡萄膜炎中心进行的回顾性研究：结果：共纳入 39 名患者的 50 只眼睛。平均最佳矫正视力（BCVA）和视网膜中央厚度（CRT）在植入 FAi 后 36 个月内保持稳定（分别为 61.04 对 70.25 个字母和 370.8 对 332.5 µm）。36个月后的复发率为34%（17眼），其中82%（14眼）在植入FAi前接受了大剂量皮质类固醇治疗。平均眼压（IOP）保持不变（13.38 对 15.74 mmHg），而大多数法眼（14 眼中的 13 眼）需要进行白内障手术：我们的研究表明，在临床实践中，FAi 能有效预防非感染性葡萄膜炎复发长达三年，与随机临床试验结果不相上下。在使用 FAi 之前接受过大剂量皮质类固醇治疗的患者早期复发的风险较高，应考虑按计划重新治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.

期刊最新文献

Acinetobacter baumannii Endogenous Endophthalmitis Presenting with Iris Nodules. Autoimmune Retinopathy Following COVID-19: A Case Report. Helicobacter pylori and Its Treatment Impact on Immune-Mediated Ocular Diseases. Epidemiology of Intermediate Uveitis. Limited Utility of Keratic Precipitate Morphology as an Indicator of Underlying Diagnosis in Ocular Inflammation.